[Clinical studies on sulbactam/cefoperazone in the field of obstetrics and gynecology].
Sulbactam (SBT), a new beta-lactamase inhibitor, in combination with cefoperazone (CPZ) was studied for the clinical efficacy in the field of obstetrics and gynecology. SBT/CPZ was given to 5 cases with the following infections; 2 of pyometra, 2 of endometritis and 1 of abscess of adnexa. Clinical efficacy was good in 3 cases and poor in 2 cases. Bacteriologically, only 1 strain of P. vulgaris was beta-lactamase producer but was persisted after treatment. Neither side effects nor abnormal laboratory findings was observed.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002438:Cefoperazone / Q000008:administration & dosage*; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D010397:Penicillanic Acid / Q000008:administration & dosage*; D011247:Pregnancy; D013407:Sulbactam; D065093:beta-Lactamase Inhibitors
D004338:Drug Combinations; D065093:beta-Lactamase Inhibitors; D002438:Cefoperazone; D010397:Penicillanic Acid; D013407:Sulbactam